Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Clarke, Ryon H ^a   Moosa, Shayan ^a   Anzivino, Matthew ^a   Wang, Yi ^a   Floyd, Desiree Hunt ^a,b   Purow, Benjamin W ^a,b   Lee, Kevin S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; RADIOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIOSENSITIVITY; RADIOSENSITIZATION; TISSUE OXYGENATION; TUMOR XENOGRAFT; ANIMAL; ANOXIA; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLIOMA; NEOPLASM; NUDE MOUSE; PATHOLOGY; PROCEDURES; RADIATION DOSE; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANOXIA; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OXYGEN; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY;

EID: 84908584286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111199     Document Type: Article

References (58)

1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, et al. (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 Suppl 2: ii1-56.
2. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, et al. (2009) Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13: 701-718.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
4. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, et al. (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7: 134-153.
5. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, et al. (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23: 4681-4689.
6. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P (1994) Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29: 427-431.
7. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, et al. (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10: 8177-8184.
8. Knisely JP, Rockwell S (2002) Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am 12: 525-536.
9. Coleman CN, Turrisi AT (1990) Radiation and chemotherapy sensitizers and protectors. Crit Rev Oncol Hematol 10: 225-252.
10. Shrieve DC (2006) Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am 17: 67-78, v.
11. Stewart FA (1989) Modification of normal tissue response to radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 16: 1195-1200.
12. Majmundar AJ, Wong WJ, Simon MC (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309.
13. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, et al. (2009) An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)- target genes that form the core response to hypoxia. Nucleic Acids Res 37: 4587-4602.
14. Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, et al. (2007) Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 435: 221-245.
15. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967-975.
16. Dery MA, Michaud MD, Richard DE (2005) Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37: 535-540.
17. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, et al. (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2618.
18. Chapman JD (1979) Hypoxic sensitizers-implications for radiation therapy. N Engl J Med 301: 1429-1432.
19. Fulton DS, Urtasun RC, Shin KH, Geggie PH, Thomas H, et al. (1984) Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys 10: 1709-1712.
20. Kaanders JH, Bussink J, van der Kogel AJ (2002) ARCON: a novel biologybased approach in radiotherapy. Lancet Oncol 3: 728-737.
21. Kohshi K, Kinoshita Y, Imada H, Kunugita N, Abe H, et al. (1999) Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Br J Cancer 80: 236-241.
22. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, et al. (2010) Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76: 1537-1545.
23. Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 100: 22-32.
24. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, et al. (2005) Positron emission tomography for radiation treatment planning. Strahlenther Onkol 181: 483-499.
25. Grosu AL, Weber WA, Franz M, Stark S, Piert M, et al. (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63: 511-519.
26. Whitfield GA, Kennedy SR, Djoukhadar IK, Jackson A (2014) Imaging and Target Volume Delineation in Glioma. Clin Oncol (R Coll Radiol).
27. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
28. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85: 133-148.
29. Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, et al. (2009) Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 24: 879-891.
30. Seshadri M, Ciesielski MJ (2009) MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. J Cereb Blood Flow Metab 29: 1373-1382.
31. Hadjipanayis CG, Fellows-Mayle W, Deluca NA (2008) Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. Mol Ther 16: 1783-1788.
32. Lund EL, Bastholm L, Kristjansen PE (2000) Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6: 971-978.
33. Hsieh CH, Lee CH, Liang JA, Yu CY, Shyu WC (2010) Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Oncol Rep 24: 1629-1636.
34. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, et al. (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69: 4252-4259.
35. Strofer M, Jelkmann W, Metzen E, Brockmeier U, Dunst J, et al. (2011) Stabilisation and knockdown of HIF-two distinct ways comparably important in radiotherapy. Cell Physiol Biochem 28: 805-812.
36. Aboody KS, Najbauer J, Metz MZ, D'Apuzzo M, Gutova M, et al. (2013) Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med 5: 184ra159.
37. Hamza MA, Gilbert M (2014) Targeted therapy in gliomas. Curr Oncol Rep 16: 379.
38. Jackson CM, Lim M, Drake CG (2014) Immunotherapy for Brain Cancer: Recent Progress and Future Promise. Clin Cancer Res.
39. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310: 1842-1850.
40. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, et al. (2011) Current concepts and management of glioblastoma. Ann Neurol 70: 9-21.
41. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648.
42. Duong TQ, Iadecola C, Kim SG (2001) Effect of hyperoxia, hypercapnia, and hypoxia on cerebral interstitial oxygen tension and cerebral blood flow. Magn Reson Med 45: 61-70.
43. Hou H, Dong R, Li H, Williams B, Lariviere JP, et al. (2012) Dynamic changes in oxygenation of intracranial tumor and contralateral brain during tumor growth and carbogen breathing: a multisite EPR oximetry with implantable resonators. J Magn Reson 214: 22-28.
44. Hou H, Li H, Dong R, Mupparaju S, Khan N, et al. (2011) Cerebral oxygenation of the cortex and striatum following normobaric hyperoxia and mild hypoxia in rats by EPR oximetry using multi-probe implantable resonators. Adv Exp Med Biol 701: 61-67.
45. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33: 207-214.
46. Chen N, Chen X, Huang R, Zeng H, Gong J, et al. (2009) BCL-xL is a target gene regulated by hypoxia-inducible factor-1 {alpha}. J Biol Chem 284: 10004-10012.
47. Dong Z, Venkatachalam MA, Wang J, Patel Y, Saikumar P, et al. (2001) Upregulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem 276: 18702-18709.
48. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, et al. (2004) Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J 381: 761-767.
49. Huang LE (2013) Biochemistry. How HIF-1alpha handles stress. Science 339: 1285-1286.
50. Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, et al. (2013) Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells. Eur J Cancer 49: 2884-2891.
51. Luo Z, Bai M, Xiao X, Zhang W, Liu X, et al. (2014) Silencing of HIF-1alpha enhances the radiation sensitivity of human glioma growth in vitro and in vivo. Neuropharmacology.
52. Kohshi K, Yamamoto H, Nakahara A, Katoh T, Takagi M (2007) Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol 82: 297-303.
53. Beppu T, Kamada K, Yoshida Y, Arai H, Ogasawara K, et al. (2002) Change of oxygen pressure in glioblastoma tissue under various conditions. J Neurooncol 58: 47-52.
54. Liu W, Liu K, Tao H, Chen C, Zhang JH, et al. (2012) Hyperoxia preconditioning: the next frontier in neurology? Neurol Res 34: 415-421.
55. Chou CW, Wang CC, Wu CP, Lin YJ, Lee YC, et al. (2012) Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro Oncol 14: 1227-1238.
56. Dewhirst MW (2009) Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 172: 653-665.
57. Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, et al. (2006) Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66: 11736-11744.
58. Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441.